Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2022 · 10-Q
Revenue—
Net Income-$6.88M-$6.88MN/M vs Q3 2021 EPS Diluted-$0.22-$0.22N/M vs Q3 2021 Operating Income-$7,023,000N/M Operating Cash Flowderived-$2,918,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Oct 31, 2022 · 31 d after period end